In fact, although a low expression of MYO1D is related to progression in prostate cancer due to hyperactivation of histone H3K27me3 [32], an overexpression of MYO1D levels in colorectal cancer and acute myeloid leukemia causes an increase in EGFR expression, activating oncogenic pathways, and therefore promoting tumor progression [33,34]. Here, MYO1D is linked to prostate cancer.